LYEL VS MRK Stock Comparison
Performance
LYEL10/100
10/100
LYEL returned -58.96% in the last 12 months. Based on SPY's performance of -13.12%, its performance is below average giving it a score of 10 of 100.
MRK100/100
100/100
MRK returned 1.78% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.
Technicals
LYEL54/100
54/100
LYEL receives a 53 of 100 based on 14 indicators. 7 are bullish, 6 are bearish.
MRK10/100
10/100
MRK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
LYEL100/100
100/100
LYEL has missed earnings 1 times in the last 20 quarters.
MRK53/100
53/100
MRK has missed earnings 3 times in the last 20 quarters.
Profit
LYEL10/100
10/100
Out of the last 15 quarters, LYEL has had 0 profitable quarters and has increased their profits year over year on 0 of them.
MRK66/100
66/100
Out of the last 20 quarters, MRK has had 17 profitable quarters and has increased their profits year over year on 7 of them.
Volatility
LYEL43/100
43/100
LYEL has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
MRK52/100
52/100
MRK has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Analyst Price Targets
LYEL
"Analyst Price Targets" not found for LYEL
MRK68/100
68/100
21 analysts offer 12-month price targets for MRK. Together, they have an average target of 113.88, the most optimistic target put MRK at 294 within 12-months and the most pessimistic has MRK at 80.
Dividend
LYEL
"Dividend" not found for LYEL
MRK100/100
100/100
MRK's most recent dividend was $0.47 per share, based on a share price of $101.35. It was a payout ratio of 69.90% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
Lyell Immunopharma, Inc. Common Stock Summary
Nasdaq / LYEL
Healthcare
Biotechnology
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Merck & Co., Inc. Summary
New York Stock Exchange / MRK
Healthcare
Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare LYEL to other companies in the same or a similar industry.